Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa

Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa
复制标题

DOI:
10.1016/s0306-4522(02)00548-1
复制
发表时间:
2003-01-01
期刊:
影响因子:
3.3
通讯作者:
Stoessl, AJ
Stoessl, AJ
中科院分区:
医学3区
文献类型:
--
作者:
Van Kampen, JM;Stoessl, AJ

文献摘要

被引文献

相似文献

Levodopa-induced dyskinesias are abnormal involuntary movements that develop as a side-effect of long-term treatment with levodopa for Parkinson's disease. The mechanisms underlying such effects are unclear but may include abnormal stimulation of dopamine D-3 receptors. Elevations in dopamine D-3 receptor mRNA and binding are seen in the denervated striatum of hemiparkinsonian rats treated chronically with levodopa, and these changes correlate well with behavioural sensitization in this model. Further investigation of dopamine D-3 receptor involvement in levodopa-induced dyskinesias is hampered by the lack of appropriately selective ligands for this receptor. Here, in vivo administration of an antisense oligonucleotide designed to reduce striatal dopamine D-3 receptor expression provides a level of specificity not available through traditional pharmacological approaches. Following chronic treatment with levodopa, hemiparkinsonian rats received intrastriatal infusion of oligonucleotide antisense to dopamine D-3 receptor mRNA for 5 days. Antisense treatment effectively and selectively reduced striatal dopamine D-3 receptor binding and blocked behavioural sensitization to the effects of repeated levodopa.These findings confirm the importance of the D-3 receptor in the expression of behavioural sensitization to levodopa in animals with dopaminergic denervation and contribute to our limited understanding of the functional significance of this receptor. In that sensitization to the effects of repeated levodopa in this setting may be analogous to medication-induced dyskinesias in humans, our findings furthermore suggest that drugs which block D-3 function may be helpful in the treatment of dyskinesias, without necessarily exacerbating Parkinsonism. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.